Antiarrhythmic and Proarrhythmic Potential of Pharmacological Agents
Antiarrhythmic therapy in general has a problem ‘especially in the treatment of ventricular arrhythmias’ that the compounds have proarrhythmic potential which is due to the same cellular mechanism that is responsible for their antiarrhythmic properties. Drug-induced arrhythmia can be attributed to e...
Elmentve itt :
| Szerző: | |
|---|---|
| További közreműködők: | |
| Dokumentumtípus: | Disszertáció |
| Megjelent: |
2023-06-05
|
| Kulcsszavak: | Cardiac Electrophysiology, Antiarrhythmic Drugs, Proarrhythmia, Sodium Channel Inhibitors, Desethylamiodarone, Cannabidiol. |
| Tárgyszavak: | |
| doi: | 10.14232/phd.11729 |
| mtmt: | 34126416 |
| Online Access: | http://doktori.ek.szte.hu/11729 |
| Tartalmi kivonat: | Antiarrhythmic therapy in general has a problem ‘especially in the treatment of ventricular arrhythmias’ that the compounds have proarrhythmic potential which is due to the same cellular mechanism that is responsible for their antiarrhythmic properties. Drug-induced arrhythmia can be attributed to either excessive conduction slowing (e.g. with class Ia or Ic Na+ channel blockers) or excessive prolongation of ventricular action potential duration (APD) (e.g. with class III antiarrhythmic agents), or both. The aim of the presents study was to investigate the antiarrhythmic and proarrhythmic potential of some pharmacological agents. We therefore thoroughly investigated and compared the kinetics of these Na+ channel blockers to provide further experimental data and to differentiate between their antiarrhythmic and proarrhythmic properties. In the present study, conventional microelectrode and patch clamp techniques were used to measure the action potential (AP) parameters and the transmembrane ionic currents underlying the AP, respectively. The results show that GS967 inhibits INaP similarly to the class Ib antiarrhythmic drug mexiletine, but with higher potency and three fold faster offset kinetics. Both GS967 and mexiletine significantly depressed V+max at high stimulation rates. Flecainide lengthened APD only at faster stimulation frequencies having cycle length (CL) shorter than 500 ms and increased the APDs of early extrasystoles noticeably. Moreover, flecainide reduced V+max in the entire frequency range exhibiting much slower offset kinetics than mexiletine. Similarly, quinidine depressed V+max use-dependently showing slower offset kinetics than mexiletine. Although, quinidine slowed the restitution kinetics of APD, however, it exhibited a reverse rate-dependent prolongation on APD90. In addition, acute desethylamiodarone (DEA) administration exerted a mild but not reverse rate-dependent APD90 prolongation and significant V+max inhibition at short CLs. Furthermore, cannabidiol lengthened APD90 significantly at the concentration of 5 µM without changing any other AP parameter significantly. These findings suggest that the frequency dependence, restitution kinetics and onset kinetics are important electrophysiological determinants which can discriminate Na+ channel blockers with proarrhythmic and antiarrhythmic potential. Moreover, the current data suggest that compounds which do not block impulse conduction at normal heart rate and have a fast recovery such as mexiletine and GS967, can be promising for future drug development. Also the interesting big APD lengthening effect on the early extrasystole observed with flecainide would be probably useful but the effect on sodium current at normal heart rate can be potentially proarrhythmic. Furthermore, the absence of an increase in dispersion of ventricular repolarization with DEA correlates with its clinically observed lower incidence of proarrhythmia. In addition, the physicians should be aware in recognizing of the deleterious effects of compounds that affect the repolarization reserve in co-morbid or polypharmacy patient. |
|---|